Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant ...

The full manuscript, titled “Enozertinib is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-small Cell Lung Cancer with EGFR Exon 20 and Atypical Mutations,” is available online at Cancer ...

ORIC Pharmaceuticals announces scientific details of discovery and development of enozertinib: South San Francisco Saturday, November 8, 2025, 13:00 Hrs [IST] ORIC Pharmaceuticals ...

Weakened lung function diagnosis can potentially be achieved sooner in the aging process with increased monitoring.

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 15 stocks set to explode in 2026. On November 7, 2025, Summit ...

On 7, Professor Sheng Jindong from Tianjin Cancer Hospital presented oral results on the efficacy and safety of sacituzumab tirumotecan (sac-TMT) monotherapy for locally advanced or metastatic ...

Investing.com -- Oric Pharmaceuticals Inc (NASDAQ:ORIC) stock rose 1.9% in premarket trading Friday after the company published a peer-reviewed research paper on its cancer drug enozertinib in the ...

October brought several updates in the lung cancer field, ranging from notable trial results to patient-centered perspectives ...

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms ...

Akeso, Inc. (HKEX: 9926.HK) is excited to announce that the final Overall Survival (OS) analysis results from the HARMONi-A study, a Phase III study evaluating ivonescimab combined with chemotherapy ...

As India observes Lung Cancer Awareness Month, city oncologists are raising alarm over an increasing number of lung cancer ...

Scientific studies also reveal that Indian women are more likely to carry mutations such as EGFR, ALK, and ROS1, which are linked to non-small cell lung carcinoma (NSCLC)—a form of cancer increasingly ...